MX2011012659A - Terapia con vacunas para neovascularizacion coroidea. - Google Patents
Terapia con vacunas para neovascularizacion coroidea.Info
- Publication number
- MX2011012659A MX2011012659A MX2011012659A MX2011012659A MX2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A
- Authority
- MX
- Mexico
- Prior art keywords
- neovascularization
- choroidal neovascularization
- vaccine therapy
- vegfr
- peptide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 title 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000035719 Maculopathy Diseases 0.000 abstract 2
- 206010029113 Neovascularisation Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 210000003161 choroid Anatomy 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
- B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
- B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
- B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
- B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
- B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Transportation (AREA)
- Aviation & Aerospace Engineering (AREA)
- Mechanical Engineering (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009140363 | 2009-06-11 | ||
| PCT/JP2010/003871 WO2010143435A1 (en) | 2009-06-11 | 2010-06-10 | Vaccine therapy for choroidal neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012659A true MX2011012659A (es) | 2011-12-16 |
Family
ID=43308696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012659A MX2011012659A (es) | 2009-06-11 | 2010-06-10 | Terapia con vacunas para neovascularizacion coroidea. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8975229B2 (enExample) |
| EP (1) | EP2440226A4 (enExample) |
| JP (1) | JP5688587B2 (enExample) |
| KR (1) | KR20120038419A (enExample) |
| CN (1) | CN102802654A (enExample) |
| AU (1) | AU2010259797B2 (enExample) |
| BR (1) | BRPI1013025A2 (enExample) |
| CA (1) | CA2764562A1 (enExample) |
| IL (1) | IL216402A0 (enExample) |
| MX (1) | MX2011012659A (enExample) |
| RU (1) | RU2555345C2 (enExample) |
| SG (2) | SG10201403109VA (enExample) |
| TW (1) | TW201109029A (enExample) |
| WO (1) | WO2010143435A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1855707B1 (en) | 2005-02-28 | 2012-04-04 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| PL2119447T3 (pl) * | 2007-02-16 | 2013-08-30 | Oncotherapy Science Inc | Terapia szczepionkowa przeciwko neowaskularyzacji naczyniówkowej |
| FR2990352A1 (fr) | 2012-05-10 | 2013-11-15 | Univ Paris 13 | Composition immunogene comprenant un peptide derive du vegf et ses utilisations |
| JP7168228B2 (ja) * | 2017-05-19 | 2022-11-09 | 慶應義塾 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998031794A1 (fr) | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
| WO1998058053A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Human receptor tyrosine kinase, kdr |
| WO1999040118A1 (en) | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| EP1086705A4 (en) | 1998-05-20 | 2002-02-06 | Kyowa Hakko Kogyo Kk | INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR |
| AU6600400A (en) | 1999-08-13 | 2001-03-13 | Crucell Holland B.V. | Methods and means for inhibiting angiogenesis |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| AU2002362461A1 (en) | 2001-10-01 | 2003-04-14 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| DK2261249T3 (en) | 2002-09-12 | 2015-02-16 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| ES2428354T3 (es) | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
| CN1926551B (zh) | 2003-10-27 | 2010-06-16 | 罗斯塔生化科技有限责任公司 | 用于基因沉默的siRNA的设计方法 |
| JP2006215988A (ja) * | 2005-02-07 | 2006-08-17 | Ntt Docomo Kansai Inc | 認証システム、携帯端末装置及び認証方法 |
| EP1855707B1 (en) | 2005-02-28 | 2012-04-04 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| JP2006315988A (ja) | 2005-05-11 | 2006-11-24 | Mototake Shimizu | ケモカイン産生誘導効果を有する血管新生阻害物質 |
| PL2119447T3 (pl) | 2007-02-16 | 2013-08-30 | Oncotherapy Science Inc | Terapia szczepionkowa przeciwko neowaskularyzacji naczyniówkowej |
| WO2008152816A1 (en) | 2007-06-14 | 2008-12-18 | Oncotherapy Science, Inc. | Methods of identifying agents that modulate methylation of vegfr1 by smyd3 |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
-
2010
- 2010-06-08 TW TW099118513A patent/TW201109029A/zh unknown
- 2010-06-10 SG SG10201403109VA patent/SG10201403109VA/en unknown
- 2010-06-10 SG SG2011090933A patent/SG176737A1/en unknown
- 2010-06-10 MX MX2011012659A patent/MX2011012659A/es active IP Right Grant
- 2010-06-10 CA CA2764562A patent/CA2764562A1/en not_active Abandoned
- 2010-06-10 RU RU2012100241/15A patent/RU2555345C2/ru not_active IP Right Cessation
- 2010-06-10 KR KR1020117031702A patent/KR20120038419A/ko not_active Withdrawn
- 2010-06-10 WO PCT/JP2010/003871 patent/WO2010143435A1/en not_active Ceased
- 2010-06-10 JP JP2011552249A patent/JP5688587B2/ja not_active Expired - Fee Related
- 2010-06-10 CN CN2010800356548A patent/CN102802654A/zh active Pending
- 2010-06-10 US US13/377,110 patent/US8975229B2/en not_active Expired - Fee Related
- 2010-06-10 EP EP10785967.0A patent/EP2440226A4/en not_active Withdrawn
- 2010-06-10 AU AU2010259797A patent/AU2010259797B2/en not_active Expired - Fee Related
- 2010-06-10 BR BRPI1013025A patent/BRPI1013025A2/pt not_active IP Right Cessation
-
2011
- 2011-11-17 IL IL216402A patent/IL216402A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120038419A (ko) | 2012-04-23 |
| EP2440226A4 (en) | 2013-09-18 |
| IL216402A0 (en) | 2012-01-31 |
| SG10201403109VA (en) | 2014-10-30 |
| RU2012100241A (ru) | 2013-07-20 |
| RU2555345C2 (ru) | 2015-07-10 |
| CN102802654A (zh) | 2012-11-28 |
| US20120156233A1 (en) | 2012-06-21 |
| WO2010143435A1 (en) | 2010-12-16 |
| AU2010259797A1 (en) | 2011-12-08 |
| US8975229B2 (en) | 2015-03-10 |
| SG176737A1 (en) | 2012-01-30 |
| JP2012529423A (ja) | 2012-11-22 |
| CA2764562A1 (en) | 2010-12-16 |
| BRPI1013025A2 (pt) | 2016-04-05 |
| EP2440226A1 (en) | 2012-04-18 |
| TW201109029A (en) | 2011-03-16 |
| JP5688587B2 (ja) | 2015-03-25 |
| AU2010259797B2 (en) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EP2949344A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| WO2009051837A3 (en) | Vaccine nanotechnology | |
| CN107921106A (zh) | Wt1抗原肽和免疫调节剂的组合 | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| PH12015500297A1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MX2019001021A (es) | Formulaciones de liposomas. | |
| BR112015010396A2 (pt) | terapia de combinação | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| JP2017533201A5 (enExample) | ||
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| Amlie-Lefond et al. | Innate immunity for biodefense: a strategy whose time has come | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| BR112015013215A2 (pt) | proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares | |
| MX2009008750A (es) | Terapia de vacuna para neovascularizacion coroidal. | |
| SA520411067B1 (ar) | تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |